Dendritic cell (DC) vaccination represents an interesting immunotherapeutic option in the treatment of several malignancies. In multiple myeloma (MM) patients, vaccination with autologous idiotype (Id) protein-pulsed DC is feasible, but their antitumoral effectiveness was rather limited. To improve the therapeutic potential of DC therapy, we studied the immunological effects of syngeneic peripheral blood stem cell transplantation (PBSCT) given in conjunction with Id-loaded DC. Balb/c mice were inoculated i.p. with 5 × 10 5 of HOPC myeloma cells (Balb/c origin). Animals were immunized with three injections of 5 × 10 5 DC pulsed with the IgG2a HOPC or with a control immunoglobulin (Ig control ). Some experimental groups of myeloma-bearing animals received total body irradiation (7.5 Gy) and a subsequent transplant of 2 × 10 7 syngeneic peripheral blood progenitor cells (PBPC) followed by DC therapy beginning at day 10 post transplant. Animals receiving DC therapy or syngeneic PBPCT alone neither induce longterm survival nor tumor-specific CTL reactivity in vitro. In marked contrast, combination of syngeneic PBPC transplantation and subsequent DC therapy resulted in 78% survival after a follow-up of 180 days. In addition, this treatment modality conferred a generation of Id peptide-specific CD8-mediated T cell reactivity. These data provide a rationale for DC-based vaccination in multiple myeloma patients administered post syngeneic transplantation. Multiple myeloma (MM) is a malignant plasma cell disorder derived from a B cell clone.
Multiple myeloma (MM) is a malignant plasma cell disorder derived from a B cell clone. 1 Median survival time of untreated MM patients is less than 1 year. Treatment with alkylating agents induces a clinical response in about 50% of the patients and prolongs survival to a median of approximately 3 years. Although autologous 2, 3 or allogeneic stem cell transplantation 4 can improve the outcome in subgroups of patients, the course of MM is still almost invariably fatal. New therapeutic approaches to control or eradicate the malignant clone are definitely needed.
The idiotype (Id) that is expressed on the immunoglobulin (Ig) produced by B cell lymphomas and myelomas is clonally restricted to tumour cells and thus can serve as a tumour-specific antigen. Early studies by Sirisinha and Eisen 5 and Lynch et al 6 showed that immunisation with purified Ig derived from a mineral oil-induced plasmacytoma (MOPC) induced anti-idiotypic immunity in syngeneic mice. These findings could be confirmed in several other B cell tumour models. [7] [8] [9] In most of these studies, anti-Id immunity was dependent on T cells rather than on anti-Id antibodies. Bogen et al have shown that Id-specific CD4 + T cells are essential for tumour protection in the MOPC myeloma model. [9] [10] [11] [12] Several experimental and clinical data suggest that dendritic cells (DC) specialised to optimally present antigens can be used to enhance the antitumour T cell response. [13] [14] [15] [16] [17] [18] In a murine B cell lymphoma model, Flamand et al 16 have shown that a specific anti-Id immunity can be generated in the host by immunisation with DC loaded in vitro with the Id protein. This anti-Id immunity confers protection against a subsequent challenge with a lethal dose of tumour cells.
Despite the induction of minimal tumour load with highdose chemotherapy protocols followed by autologous PBPCT, the therapeutic efficacy of DC vaccination remained limited. 19 These observations may be at least partly due to the defective T cell arm of patients' immune systems. Hence, the objective of the current study was to assess whether transplantation of syngeneic PBPC can enhance the antitumoral efficacy of DC therapy. Our data show that DC-based vaccination is particularly effective in animals receiving DC therapy early after syngeneic stem cell transplantation.
Bone Marrow Transplantation

Materials and methods
Animals, tumour cells and tumour diagnosis
Balb/c (H-2 d ) mice were bred and kept in the animal facilities of our institute. All animals were housed in conventional cages, seven to 10 animals per cage, and were given non-sterilised food and water ad libitum. Cotrimoxazole was added to the water for 40 days after bone marrow transplantation.
HOPC-1F was established in culture from a mineral oilinduced Balb/c plasmacytoma, HOPC 1. It produces an IgG2a, lambda 1 light chain. HOPC myeloma cells expressed high levels (Ͼ80%) of MHC class I (H2-D d and H2-K d ), CD54, CD58 and Fas antigen, but were negative for MHC class II, NK, T cell markers and lambda idiotype. Low levels (Ͻ5%) of the antigens B7-1, B7-2, B220 and CD19 were detectable (data not shown). MOPC-315 cell line, an IgA-secreting myeloma, was used as a control target. Both cell lines were obtained from American Type Culture Collection (Manassas, VA, USA).
Animals were examined daily for palpable abdominal tumours and necropsied after death. Animals dying of myeloma exhibit bulky abdominal tumours with malignant ascites.
Proteins and peptides
HOPC-1F immunoglobulin (Ig) and the control Ig (IgA-MOPC 315) were obtained from Sigma (Deisenhofen, Germany). For ELISPOT assays the following synthetic peptides were used: pp65 495-503 (NLVPMVATV) as a control peptide, HOPC-1F CDR III light chain [214] [215] [216] [217] [218] [219] [220] [221] [222] (ALWYSNHWV) and the HOPC CDR III heavy chain 93-102 (GDYYRRYFDL). All peptides were obtained from Biosyntan, Berlin, Germany.
Bone marrow-derived dendritic cells
As previously reported by Mayordomo et al, 15 lymphocytedepleted murine bone marrow cells were cultured overnight in complete medium (CM, RPMI 1640 + 10% FCS supplemented with 5 × 10 −5 m 2-mercaptoethanol) in 24-well plates (10 6 cells in 1 ml culture medium per well), and then replated in the presence of cytokines (2.5 × 10 5 cells per well) in 1 ml CM containing recombinant murine GM-CSF (10 3 U/ml; CellConcept, Umkirch, Germany) and recombinant murine IL-4 (10 3 U/ml; CellConcept). On day 8, immature dendritic cells were harvested by gentle pipetting.
Pulsing and maturation of dendritic cells
Bone marrow-derived dendritic cells (1 × 10 6 /ml) were incubated in 1 ml OPTI-MEM (Gibco Life Technologies, Eggenstein, Germany) in a 6-well plate (Nunc, Oslo, Denmark) for 16 h at 37°C in the presence of 50 g protein (1 g/l) derived from the myeloma cell lines HOPC-1F (IgG 2a ) or MOPC-315 (IgA). Cells were then washed twice in Dulbecco's solution (PBS; Gibco, Eggenstein, Germany). Afterwards, immature DC (1 × 10 6 /ml) were incubated with murine TNF-␣ (1000 U/ml; CellConcept) in OPTI-MEM medium (Life Technologies) for 16 h at 37°C and 5% CO 2 . Before in vivo use, matured DC were washed twice in Dulbecco's solution. By flow cytometric analysis, these matured DC expressed high levels of CD45 (95% ± 2.3), CD11c (82% ± 1.9), CD18 (90% ± 3.6), CD80 (86% ± 4.2), CD86 (82% ± 3.9), class I (92% ± 2.1) and class II MHC (91% ± 1.9) antigens. Moreover, morphological analysis and MLR assay exhibited typical properties of mature DC (data not shown).
Immunisation
Two days post inoculation of 5 × 10 5 HOPC-1F myeloma cells (i.p.) Balb/c mice were immunised with three subcutaneous injections (given in the flank) of 5 × 10 5 pulsed or unpulsed DC (in a volume of 200 l), at weekly intervals. Other control groups had been treated with 50 g HOPC-1F-IgG 2a (s.c.) or the same dose of the control protein given with incomplete Freund's adjuvant (IFA, Sigma; 50 l IFA admixed with 50 l protein). Myeloma-bearing animals receiving syngeneic PBPC were treated with the identical immunisation protocol as described above beginning on day 10 post transplant.
Generation of CTL
Seven days after the last immunisation, tumour-bearing animals were killed under ether anaesthesia. The spleens were removed and pressed through wire mesh screens to obtain single cell suspensions. Mononuclear cells were isolated by density gradient centrifugation (Lympholyte M; Cedarlane Laboratories, Hornby, Canada Cr release assay for their ability to kill HOPC myeloma cells.
Cytotoxicity assay
Target cells were obtained from cell culture and were labelled with 200 Ci of NaCrO 4 (Amersham-Buchler, Braunschweig, Germany) in 0.5 ml complete medium for 1 h. They were washed three times with complete medium and added at a concentration of 1 × 10 4 cells/well in roundbottomed microtitre plates (Nunc). Effector cells were added at various effector/target ratios in a final volume of 200 l/well. The plates were incubated for 4 h at 37°C in a humid atmosphere with 5% CO 2 . Maximum chromium release was ensured by the addition of 10% Triton-X, and spontaneous release was assessed by adding complete medium (RPMI 1640 + 10% FCS) to the target cells. The culture supernatant was harvested semi-automatically with a Scatron Titertek System (Scatron, Suffolk, UK) and counted in a gamma counter (Beckmann, Heidelberg, Germany). The percentage of specific lysis was calculated as (experimental cpm − spontaneous cpm)/(maximum cpm − spontaneous cpm) × 100. All determinations were made in hexaplicate.
Blocking inhibition assays with monoclonal antibodies (MoAbs)
For MoAb-blocking experiments, effector cells or target cells were incubated for 30 min with MoAbs against CD4 (clone RM4-4, Pharmingen, San Diego, CA, USA), CD8 (clone KT15; Serotec, Wiesbaden, Germany) and MHC class I (H-2K d clone SF1-1.1; Pharmingen) at a final dilution of 1:10. As a control, anti-mouse H-2D b (clone KH95; Pharmingen) was used. The cells were washed twice with complete medium and tested in a chromium release assay as described above.
ELISPOT assay
Interferon-␥ ELISPOT assays were done as described by Okamoto et al. 20 One week after the last vaccination, primed splenocytes were harvested and incubated with peptide-pulsed DC for 4 h in OPTI-MEM medium (MNC:DC ratio 10:1). ELISPOT assays were performed in nitrocellulose-backed 96-well plates (MAHA-S45; Milipore, Bedford, UK), with the anti-mouse interferon-␥ antibodies R4-6A2 for capture and biotinylated XMG1.2 for detection (both Pharmingen). Spots were detected using chromogenic peroxidase substrate (Sigma), and quantified using the Bioreader 2000 (Biosys, Freiberg, Germany).
Hematopoietic stem cell transplantation (SCT)
Transplantation was performed as described elsewhere. 21 In brief, a Cs 137 source was used for total body irradiation (TBI) of the recipients. A lethal dose of 7.5 Gy was chosen for conditioning. Syngeneic Balb/c mice intended to serve as donors for PBPC were splenectomized under general anesthesia at least 14 days prior to the donation of PBPC. Starting 5 days prior to collection of PBPC, 5 g of rhumet-G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) were injected s.c. twice daily; the last injection of Filgrastim was given 2 h prior to harvesting the PBPC. The mice were then anticoagulated by heparin, anesthetised and killed by cervical dislocation. The peripheral blood was collected under sterile conditions by dissection of both carotid arteries. Erythrocytes and debris were removed by density gradient centrifugation for 20 min at 1500 g at room temperature. Two days post i.p. inoculation of 1 × 10 5 HOPCmyeloma cells animals received 7.5 Gy of TBI followed by an i.v. injection of 2 × 10 7 PBPC.
Immunophenotyping
For marker analysis, spleen cells were incubated with appropriate primary and secondary antibodies and analysed using a flow cytometer (FACScan; Becton Dickinson, Mountain View, CA, USA). The following antibodies were used: 
TNF-␣ ELISA assay
As described above, splenocytes obtained from animals which had been immunised with pulsed DC or the complete myeloma protein, were incubated with syngeneic loaded DC in a ratio of 5:1 (splenocytes:DC) in a 24-well plate at 37°C. After 48 h of incubation, supernatants were harvested and tested for TNF-␣ in a standardised ELISA Assay (TiterZyme murine TNF-␣; PerSeptive Diagnostics, Cambridge, MA, USA). Cytokine levels were calculated with reference to standard curves which were constructed from the analysis of supernatants containing known amounts of recombinant TNF-␣.
Statistical analysis
Survival of animals was calculated according to the method of Kaplan and Meier. Group comparisons were made by Student's t-test. The calculations were done on a PC with 'Statistica' data analysis software (StatSoft, Tulsa, OK, USA). days) were administered (see Figure 1 ). To determine whether this therapeutic concept resulted in a myelomaspecific CTL response, tumour-bearing animals were killed 1 week after the last vaccination. As depicted in Figure 2 , no specific cytotoxic activity against the HOPC-1F myeloma and no significant numbers of IFN-␥-secreting cells reacting to idiotype-specific peptides could be measured (data not shown).
Results
Id-loaded dendritic cells did not induce long-term survival in myeloma-bearing animals
High antitumoural efficacy of DC therapy after syngeneic PBPCT
To evaluate the antitumoural efficacy of Id-pulsed DC syngeneic transplantation, animals received 2 days after inoculation of 5 × 10 5 HOPC cells, a lethal dose of TBI (7.5 Gy) followed by a transfer of 2 × 10 7 syngeneic G-CSF-mobilised PBPC. This procedure resulted in a significant pro- In marked contrast, animals receiving vaccination with DC pulsed with the HOPC-myeloma protein experienced a powerful antimyeloma effect. Eleven of 14 animals (78%) were alive and free from myeloma after an observation per- 
Induction of idiotype-specific T cell reactivity after DC therapy post transplant
To test whether bone marrow-derived DC pulsed with the myeloma-specific protein are capable of inducing a tumourspecific T cell response post syngeneic PBPCT, splenocytes of treated animals were harvested 1 week after the last vaccination and restimulated for 5 days in vitro with syngneic Id-pulsed DC. As shown in Figure 5a , T cells primed with Ig HOPC -loaded DC exhibited relevant cytotoxic activity against the HOPC-myeloma target whereas the control target MOPC 315 was not attacked (data not shown). In parallel, supernatants of these cell cultures contained signifi- Bone Marrow Transplantation cantly higher levels of TNF-␣ when compared to the control groups (Figure 5b ; DC-Ig-HOPC vs DC-Ig-control P Ͻ 0.005, DC-Ig-HOPC vs DC only P Ͻ 0.005).
To look for specific reactivity against epitopes derived from the CDRIII region of the HOPC immunoglobulin, ELISPOT assays were conducted. In transplanted recipients treated with Ig HOPC -pulsed DC or with the complete Ig HOPC (admixed with IFA) a significant increase in the frequency of tumour-specific (heavy chain-derived CDRIII-peptide) T cells could be detected (see Table 1 ). DC-therapy induced higher numbers of IFN-␥-secreting spot forming cells if compared to the experimental groups receiving Ig HOPC (DCIg HOPC vs Ig HOPC , P Ͻ 0.001).
Idiotype-primed CD8 + T cells specifically lyse HOPC myeloma cells
To investigate the MHC restriction of the antigen recognition of these CTL, the ability of CD4, CD8 and MHC I antibodies to inhibit cytotoxicity against the MHC class II (+ IFA) or unpulsed DC, as described in Methods. One week after the last vaccination splenocytes were harvested and restimulated with unpulsed DC or DC pulsed with different peptides in an ELISPOT assay. Data were pooled from three different experiments.
negative HOPC myeloma was tested. The results, illustrated in Figure 6 , indicate a MHC I-mediated, CD8-dependent antigen recognition. In addition, Ig HOPC -primed enriched CD8 + T cells specifically killed the HOPC target without affecting the control target MOPC whereas Id-primed CD4 + T cells elicited no relevant effects.
To determine the MHC-restriction of Id-specific CTL generated from mice receiving specifically pulsed DCs ( Figure 7 ) the ability of CD4, CD8 and MHC I antibodies to inhibit cytotoxicity against the MHC class II negative HOPC myeloma was tested. The results indicate that Idprimed CTL mediated an MHC class I and CD8-dependent idiotype recognition.
Discussion
In the present study, we show that treatment with syngeneic Id-loaded DC elicits most powerful antitumoural effects when administered post syngeneic PBPCT. Our data provide evidence that Id-specific DC therapy generates a tumour-specific immune response mediated by CD8 + T cells. Furthermore, this vaccination concept enhances the frequency of myeloma CDR III peptide-specific T cells.
Dendritic cells are large, bone marrow-derived, professional antigen-presenting cells which efficiently stimulate naive T cells to recognise and respond to specific antigens. Several experimental studies have documented that DC pulsed with peptide epitopes induce cytotoxic immune responses against various tumour antigens. [13] [14] [15] [16] [17] [18] In our present study, DC therapy failed to induce a lasting therapeutic effect in animals bearing high numbers of HOPC myeloma cells. These observations could be supported by studies from Bogen. 22 Utilising T cell receptor (TCR) transgenic mice specific for a model tumour antigen expressed on the MOPC-315 myeloma, they showed that in animals with high tumour burden the vast majority of autologous idiotype-specific T cells in the peripheral lymphoid organs and in the tumour were functionally deleted. Yi et al 23 reported that in myeloma patients at an early stage of disease, T cell responses to autologous idiotype protein were significantly higher than in patients with more advanced stage. These data show that the induction of T cell tolerance to idiotype proteins represents an important tumour escape mechanism in advanced disease of multiple myeloma. Besides the induction of tumour antigen-specific T cell tolerance, several other strategies of malignant cells to avoid recognition by cytotoxic T lymphocytes have been described. 24 For example in our model, HOPC myeloma cells produce high amounts of interleukin-10 (data not shown), an immunosuppressive cytokine capable of inhibiting antitumoural T cell immunity. 25 Several clinical trials were initiated using pulsed dendritic cells derived from monocytes [26] [27] [28] or CD34 + progenitor cells. 29 Wen and coworkers 26 treated advanced-stage myeloma patients with idiotype-pulsed DC. Id-specific immune responses were generated, characterised by MHC-dependent T cell proliferative responses with cytokine release and the production of anti-Id antibodies. The immune responses were associated with a transient minor fall in the serum Id level and were not ablated by high-dose myeloablative chemotherapy. Reichardt et al 19 reported on 12 MM patients who had been immunised with Id-pulsed DC given 3 to 7 months post high-dose therapy and autologous PBPCT. Two of 12 patients developed an Id-specific, cellular immune response and remained in complete remission whereas patients achieving only partial responses post transplant did not produce any detectable tumour-specific activity post DC therapy. These data show that vaccination with Id-pulsed DC can elicit humoral and in some cases specific T cell responses. However, despite the induction of a status of minimal tumour load by autologous stem cell transplantation, the therapeutic effectiveness of idiotype vaccination concepts remained limited. One possible explanation of these findings may rely on the induction of T cell tolerance to the myeloma idiotype proteins, as described above.
To overcome this problem, we conducted DC vaccination studies after transfer of naive unprimed T cells contained in the graft of syngeneic healthy stem cell donors. This therapeutic concept resulted in very powerful antimyeloma effects with the majority of animals being tumour free after an observation period of more than 180 days post PBPCT. In addition, tumour challenge experiments in surviving animals revealed that DC therapy produced longterm antitumoural immunity. In a murine B cell lymphoma model, Kwak et al 8 showed that vaccination with the tumour-derived immunoglobulin given 14 days post transplant induced both humoral and cellular antitumour responses and protected some mice from an otherwise lethal tumour dose. In our study, striking therapeutic effects were detected when the first dose of idiotype-pulsed DC was administered on day 10 post syngeneic PBPCT during hematopoietic engraftment. The rationale to attempt tumour vaccination in the early post-transplant period during immune reconstitution is the potential to skew the developing T cell repertoire towards the recognition of tumour antigens. Consistent with this hypothesis are data generated by Mackall et al 30 who found that the spectrum of antigen specificities of the polyclonal T cell population that repopulates after SCT is influenced by encountering antigens in the early phase post transplant during engraft- ment. Consequently, the precursor frequency of tumour antigen-specific T cells may be significantly increased if vaccination strategies were carried out during this interval. These observations could be supported by our findings that treatment with Id loaded DC post syngeneic PBPCT resulted in a significant increase of Id peptide-specific T cells. In addition, the current study shows that DC therapy provides the most effective vaccination concept in generating Id-specific T cells if compared to those treatment modalities using unpulsed DC or the complete idiotype protein admixed with IFA (see Table 1 ) documenting that optimal antigen presentation could be accomplished by utilising specifically loaded matured dendritic cells only.
Several experimental and clinical studies provide evidence for the existence of CD4 + T cells capable of recognising myeloma idiotype-specific determinants. [9] [10] [11] [12] 17 In spite of the fact that the vast majority of myelomas failed to express MHC class II molecules, CD4 + T cells may play an important role in tumour immunity. Qin and Blankenstein 31 recently showed that cellular immunity against MHC class II negative tumours can be mediated by CD4 + T cells through an IFN-␥-dependent mechanism. In the MOPC-315 plasmocytoma model, Bogen and coworkers showed that the adoptive transfer of a CD4 + T cell clone specific for a defined peptide of the -light chain variable region of the Ig elicited specific antitumoral effects. 12 As expected, Id-primed CD4 + T cells did not exhibit relevant cytotoxicity against the myeloma target in a chromium release assay in our model. It cannot be ruled out that T helper cells support CD8 effector cells by releasing type 1 cytokines (IFN-␥, GM-CSF and TNF-␣) and may act by inflammatory cytokine effects on nonhematopoietic cells, as shown by Qin and Blankenstein. 31 Consistent with this hypothesis, Cull et al 27 reported two myeloma patients responding with an idiotype-specific Th1-directed immune response after receiving a combination of Id-pulsed DC and GM-CSF.
The data presented here indicate that vaccination with idiotype protein-pulsed DCs generate a tumour-specific class I-restricted T cell response. Similar findings could be obtained in an allogeneic bone marrow transplant setting. Utilising the same myeloma model we recently showed that immunisation of healthy MHC-identical bone marrow donors with the HOPC-derived idiotype protein induced a powerful antitumoural effect post transplant in which Idspecific CD8 + T cells were involved. 32 These data are in line with recent studies in humans by Li et al 33 demonstrating that idiotype-specific CD8 + T cells derived from immunised healthy stem cell donors can recognise and kill fresh autologous myeloma cells. In the autologous setting, Ö sterborg and coworkers 34 treated myeloma patients with the purified serum M-component by repeated intradermal injections together with soluble granulocyte-macrophage colony-stimulating factor (GM-CSF). In the majority of patients an Id-specific predominantly MHC class I-restricted type T cell response could be detected. To further elucidate the role of CD4 and CD8
+ T cell subsets in eradicating residual tumour cells in vivo depletion studies using cytotoxic antibodies directed against CD4 and CD8 antigens are required.
Taken together, our data show that vaccination concepts with Id protein-pulsed DCs elicit strong anti-myeloma effects when administered in the context of syngeneic PBPCT. These findings provide a rationale for the use of idiotype protein-pulsed DCs in myeloma patients after allogeneic stem cell transplantation in which no clinically overt graft-versus-host disease occurred.
